Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Asset Writedowns and Impairment (2020 - 2025)

Sight Sciences (SGHT) has 6 years of Asset Writedowns and Impairment data on record, last reported at $132000.0 in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 447.37% year-over-year to $132000.0; the TTM value through Dec 2025 reached $129000.0, up 221.7%, while the annual FY2025 figure was $129000.0, 221.7% up from the prior year.
  • Asset Writedowns and Impairment reached $132000.0 in Q4 2025 per SGHT's latest filing, up from -$64000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $290000.0 in Q3 2022 and bottomed at -$218000.0 in Q4 2023.
  • Average Asset Writedowns and Impairment over 5 years is $48550.0, with a median of $29500.0 recorded in 2024.
  • Peak YoY movement for Asset Writedowns and Impairment: skyrocketed 544.44% in 2022, then tumbled 3214.29% in 2023.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $199000.0 in 2021, then crashed by 96.48% to $7000.0 in 2022, then crashed by 3214.29% to -$218000.0 in 2023, then surged by 82.57% to -$38000.0 in 2024, then skyrocketed by 447.37% to $132000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $132000.0 in Q4 2025, -$64000.0 in Q3 2025, and $82000.0 in Q2 2025.